Current Atherosclerosis Reports

, Volume 2, Issue 1, pp 1–4

Poor compliance: The hidden risk factor

  • John C. LaRosa
Invited Commentary

Conclusions

Poor compliance with prescribed regimens remains a potent barrier to good outcomes in coronary heart disease and other chronic diseases. Such poor compliance is related to disease, patient, provider, and treatment factors and has yet to be fully understood. In general, the less complex the regimen, the better informed the patient and the physician, and the more serious the disease, the better the compliance.

That said, research information on compliance has been somewhat stagnant for several years. There have been very few new approaches that have broken new ground or significantly enhanced or altered correct approaches. It is probably necessary that future research involve nonmedical disciplines including motivational psychology and even advertising. A good deal of such research should be specifically directed toward improving compliance in asymptomatic patients who are nevertheless at substantial risk of future catastrophic events. Until we are more successful at reproducibly improving compliance in high-risk, but asymptomatic, patients, the potential benefits of regimens whose efficacy is already very clear will remain unfulfilled.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    LaRosa JC, He J, Vupputuri S: Effect of statin drug treatment on risk of coronary heart disease: a meta-analysis of randomized, controlled trials. JAMA, 1999, in press.Google Scholar
  2. 2.
    Kannel W: Clinical misconceptions dispelled by epidemiological research. Circulation 1995, 92:3350–3360.PubMedGoogle Scholar
  3. 3.
    Random House Dictionary edn. 2. New York: 1982.Google Scholar
  4. 4.
    Elliott WJ: Compliance strategies. Curr Opin Nephrol Hypertens 1994, 3:271–278.PubMedCrossRefGoogle Scholar
  5. 5.
    Delacretaz E, Michalopoulos PG, Ruiz J, et al.: Management of hyperlipidaemia after coronary revascularisation: follow up study. BMJ 1998, 316:1499.PubMedGoogle Scholar
  6. 6.
    Shepherd J, Pratt M: Prevention of coronary heart disease in clinical practice: a commentary on current treatment patterns in six European countries in relation published recommendations. Cardiology 1996, 87:1–5.PubMedCrossRefGoogle Scholar
  7. 7.
    Avorn J, Monette J, Lacour A, et al.: Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998, 279:1458–1462.PubMedCrossRefGoogle Scholar
  8. 8.
    Strandberg TE, Lehto S, Pyorala A, et al.: Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland. Eur Heart J 1997, 18:1725–1727.PubMedGoogle Scholar
  9. 9.
    Andrade SE, Walker AM, Gottlieb LK, et al.: Discontinuation of antihyperlipidemic drugs—do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995, 332:1125–1131.PubMedCrossRefGoogle Scholar
  10. 10.
    McDermott MM, Schmitt B, Wallner E: Impact of medication nonadherence on coronary heart disease outcomes: a critical review. Arch Intern Med 1997, 157:1921–1929.PubMedCrossRefGoogle Scholar
  11. 11.
    Luepker RV: Patient adherence: a “risk factor” for cardiovascular disease. Heart Dis Stroke 1993, 2:418–421.PubMedGoogle Scholar
  12. 12.
    Sung JC, Nichol MB, Venturini F, et al.: Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. Am J Manag Care 1998, 4:1421–1430.PubMedGoogle Scholar
  13. 13.
    Chockalingam A, Bacher M, Campbell N, et al.: Adherence to management of high blood pressure: recommendations of the Canadian Coalition for High Blood Pressure Prevention and Control. Can J Pub Health 1998, 89:I5-I7.Google Scholar
  14. 14.
    Burke LE, Dunbar-Jacob JM, Hill MN: Compliance with cardiovascular disease prevention strategies: a review of the research. Ann Behav Med 1997, 19:239–263.PubMedCrossRefGoogle Scholar
  15. 15.
    Nieto FJ, Alonso J, Chambless LE, et al.: Population awareness and control of hypertension and hypercholesterolemia: The Atherosclerosis Risk in Communities study. Arch Intern Med 1995, 155:677–684.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2000

Authors and Affiliations

  • John C. LaRosa
    • 1
  1. 1.SUNY Health Science CenterState University of New York, BrooklynBrooklynUSA

Personalised recommendations